Related Experiment Video

Updated: Aug 15, 2026

Intravital Video Microscopy Measurements of Retinal Blood Flow in Mice
10:16

Intravital Video Microscopy Measurements of Retinal Blood Flow in Mice

Published on: December 26, 2013

Multifunctional drugs for endothelial dysfunction in diabetes and glaucoma

Paul L Wood1

  • 1OxoN Medica Inc, 385 Oyster Point Boulevard, Suite 9A, South San Francisco, CA 94080, USA. pwood@oxonmedica.com

Idrugs : the Investigational Drugs Journal
|June 6, 2003
PubMed

Insights

Endothelial dysfunction, driven by oxidative stress, disrupts normal cell function by altering key mediators like nitric oxide. This review explores its role in diabetes and glaucoma, advocating for multifunctional drugs.

Area of Science:

  • Biochemistry
  • Pathophysiology
  • Pharmacology

Background:

  • Endothelial dysfunction involves complex biochemical alterations in endothelial cells.
  • Increased oxidative stress is a primary initiator of these pathological changes.
  • Key mediators affected include nitric oxide (NO), superoxide, and endothelin.

Purpose of the Study:

  • To review the current understanding of endothelial dysfunction in diabetes.
  • To review the current understanding of endothelial dysfunction in glaucoma.
  • To advocate for the evaluation of multifunctional drugs for these conditions.

Main Methods:

  • Literature review of endothelial dysfunction in diabetes and glaucoma.
  • Analysis of the role of oxidative stress and key mediators.
  • Assessment of potential therapeutic strategies.

Main Results:

  • Endothelial dysfunction is characterized by an imbalance in mediators like NO and endothelin.
  • Oxidative stress significantly contributes to endothelial cell dysfunction.
  • Multifunctional drugs may offer a promising therapeutic avenue.

Conclusions:

  • Endothelial dysfunction is a critical factor in diabetes and glaucoma.
  • Targeting oxidative stress and mediator balance is crucial.
  • Further research into multifunctional drugs is warranted for these diseases.

More Related Videos

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats07:41

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...